Effect of antiretroviral therapy in thromboregulation through the hydrolysis of adenine nucleotides in platelets of HIV patients

Biomedicine and Pharmacotherapy

Volumn 79, Issue , 2016, Pages 321-328

  Rezer, João Felipe P ^a   Souza, Viviane C G ^a   Thorstenberg, Maria Luiza P ^a   Ruchel, Jader B ^a   Bertoldo, Tatiana M D ^a   Zanini, Daniela ^a   Silveira, Karine L ^a   Leal, Claudio A M ^a   Passos, Daniela F ^a   Gonçalves, Jamile F ^a   Abdalla, Fátima H ^a   Schetinger, Maria Rosa C ^a   Leal, Daniela B R ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

ADA; Adenosine; AIDS; HAART; NTPDase

Indexed keywords

5' NUCLEOTIDASE; ADENINE NUCLEOTIDE; ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ANTIRETROVIRUS AGENT; CD39 ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADENOSINE DEAMINASE; LEUKOCYTE ANTIGEN; LIPID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEAMINATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; COMPLICATION; ENZYMOLOGY; HIV INFECTIONS; METABOLISM; THROMBOSIS;

5'-NUCLEOTIDASE; ADENINE NUCLEOTIDES; ADENOSINE DEAMINASE; ADULT; ANTIGENS, CD; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD COAGULATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; HYDROLYSIS; LIPIDS; PLATELET AGGREGATION; THROMBOSIS;

EID: 84962539179     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.02.008     Document Type: Article

References (46)

1. Klimas N., Koneru A.O.B., Fletcher M.A. Overview of HIV. Psychosom. Med. 2008, 70(5):523-530.
2. Marin B., et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (London, England) 2009, 23(13):1743.
3. Palella F.J., Phair J.P. Cardiovascular disease in HIV infection. Curr. Opin. HIV AIDS 2011, 6(4):266.
4. Blanchard D.G., et al. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J. Am. Coll. Cardiol. 1991, 17(6):1270-1276.
5. de Castro S., et al. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J. Am. Coll. Cardiol. 1994, 24(4):1018-1024.
6. Barbaro G., et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. New Engl. J. Med. 1998, 339(16):1093-1099.
7. Butt A.A., et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch. Intern. Med. 2011, 171(8):737-743.
8. Wajchenberg B.L. Disfunção endotelial no diabetes do tipo 2. Arq. Bras. Endocrinol. Metabol. 2002, 46:514-519.
9. Brydon L., Magid K., Steptoe A. Platelets, coronary heart disease, and stress. Brain Behav. Immun. 2006, 20(2):113-119.
10. Dockrell M.E., et al. Platelet aggregation in young men with contrasting predisposition to high blood pressure. Am. J. Hypertens. 1999, 12(2):115-119.
11. Robson S.C., Sévigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2006, 2(2):409-430.
12. Tsegaye T.S., et al. latelet activation suppresses HIV-1 infection of T cells. Retrovirology 2013, 10(1):48.
13. Ralevic V., Burnstock G. Involvement of purinergic signalingin cardiovascular diseases. Drug News Perspect. 2003, 16:133-140.
14. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb. Haemost. 2008, 466.
15. Kahner B.N., Shankar H., Murugappan S., Prasad G.L., Kunapuli S.P. Nucleotide receptor signaling in platelets. J. Thromb. Haemost. 2006, 4:2317-2326.
16. Schetinger M.R.C., et al. NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. Biofactors 2007, 31(2):77-98.
17. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedeberg Arch. Pharmacol. 2000, 362:299-309.
18. Becker L.V., Rosa C.S., Souza V.C.G., Bagatini M.D., Casali E.A., Leal C.A., Silva J.C., Moretto M.B., Pinheiro F.V., Morsch V.M., Schetinger M.R., Leal D.B. Activities of enzymes that hydrolyze adenine nucleotides in platelets from patients with rheumatoid arthritis. Clin. Biochem. 2010, 43:1096-1100.
19. Spanevello R.M., et al. Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients. J. Neurol. 2010, 257(1):24-30.
20. Lunkes G.I., et al. Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies. Thromb. Res. 2003, 109(4):189-194.
21. Maldonado P.A., Corrêa M.C., Becker L.V., Flores C., Moretto M.B., Morsch V., Schetinger M.R.C. Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in patients with uterine cervix neoplasia. Clin. Biochem. 2008, 41:400-406.
22. Souza V.d.C.G., et al. Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of Chagas disease. Purinergic Signal. 2012, 8(4):753-762.
23. Bagatini M.D., Martins C.C., Battisti V., Spanevello R.M., Gasparetto D., Rosa C.S., Gonçalves J.F., Schetinger M.R., Santos R.B., Morsch V.M. Hydrolysis of adenine nucleotides in platelets from patients with acute myocardial infarction. Clin. Biochem. 2008, 41:1181-1185.
24. Pilla C., et al. ATP diphosphohydrolase activity (apyrase: EC 3. 6. 1.5) in human blood platelets. Platelets 1996, 7(4):225-230.
25. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72(1):248-254.
26. Giusti G., Galanti B. Colorimetric method. Methods Enzym. Anal. 1984, 315-323.
27. Douek D.C., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417(6884):95-98.
28. Gordon E.L., et al. The hydrolysis of extracellular adenine nucleotides by arterial smooth muscle cells: regulation of adenosine production at the cell surface. J. Biol. Chem. 1989, 264(32):18986-18995.
29. Kauffenstein G., et al. NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc. Res. 2010, 85(1):204-213.
30. Stafford N.P., et al. Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood. Arterioscler. Thromb. Vasc. Biol. 2003, 23(10):1928-1933.
31. Sévigny J., et al. Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 2002, 99(8):2801-2809.
32. Sitkovsky M.V., Ohta A. The 'danger'sensors that STOP the immune response: the A2 adenosine receptors. Trends Immunol. 2005, 26(6):299-304.
33. Haskó G., Pacher P. A2 A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leukoc. Biol. 2008, 83(3):447-455.
34. R.E. Rumbaut, P. Thiagarajan, Platelet-vessel wall interactions in hemostasis and thrombosis, Synthesis Lectures on Integrated Systems Physiology: From Molecule to Function, 2 (1) 2010, pp. 1-75.
35. Portal sobre AIDS, doenças sexualmente transmissíveis e hepatites virais Ministério da Saúde (access date 17.09.12). http://www.aids.gov.br/.
36. Hollmig K., Beck S., Doll D. Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors. Eur. J. Med. Res. 2001, 6(3):112-114.
37. Mangili A., et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin. Infect. Dis. 2006, 43(11):1482-1489.
38. Kaplan R.C., et al. Low CD4+ T cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (London, England) 2008, 22(13):1615.
39. Periard D., et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin. Infect. Dis. 2008, 46(5):761-767.
40. Kinugawa T., et al. Catabolism of adenine nucleotides favors adenosine production following exercise in patients with chronic heart failure. J. Card. Fail. 2006, 12(9):720-725.
41. Haskó G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004, 25(1):33-39.
42. Micieli E., et al. Venous and arterial thrombosis in patients with HIV infection. Blood Coagul. Fibrinolysis 2007, 18(3):259-263.
43. Crum-Cianflone N.F., Weekes J., Bavaro M. Thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDs 2008, 22(10):771-778.
44. Vittecoq D., et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003, 17:S70-S76.
45. Atkinson B., et al. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cells. Mol. Dis. 2006, 36(2):217-222.
46. Leal D.B., et al. NTPDase activity in human lymphocytes is not affected by therapeutic doses of anti-HIV drugs. Biomed. Pharmacother. 2011, 65(8):594-596.